Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2024-206733

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Blood (2024) 144 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2024-203009

Published: 2024

Journal Articles

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Frederic Baron, Myriam Labopin, Jurjen Versluis, Jan Vydra, Peter A. Von Dem Borne, Emma Nicholson, Didier Blaise, Stephen Robinson, Jr., Aleksandr Kulagin, Sr., Claude-Éric Bulabois, Montserrat Rovira, Patrice Chevallier, Édouard Forcade, Jenny Louise Byrne, Jaime Sanz Caballer, Annalisa Ruggeri, Mohamad Mohty, Fabio Ciceri

Blood (2023) 142 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2023-186293

Published: 2023

Journal Articles

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, Maria Pilar Gallego Hernanz, Matthias Eder, Peter A. Von Dem Borne, Gerard Socié, Patrice Chevallier, Edouard Forcade, Andreas Neubauer, Frederic Baron, Ali Bazarbachi, Gesine Bug, Arnon Nagler, Christoph Schmid, Jordi Esteve, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2023-182834

Published: 2023

Journal Articles

Randomized Trial of Prophylactic Donor Lymphocyte Infusion with Positively Selected CD4+ T Cells after HLA-Identical Allogeneic Stem Cell Transplantation

Joost Van Der Hem, Peter Van Balen, Sabrina Veld, Peter A. Von Dem Borne, Danielle Van Lammeren, Tjeerd Snijders, Jaap Jan Zwaginga, Hendrik Veelken, Rosa De Groot, Inge Jedema, Liesbeth C. de Wreede, Constantijn Halkes, J.H. Frederik Falkenburg

Blood (2023) 142 (Supplement 1): 6887.

https://doi.org/10.1182/blood-2023-188843

Published: 2023

Journal Articles

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Nour Moukalled, Myriam Labopin, Jurjen Versluis, Gerard Socié, Didier Blaise, Urpu Salmenniemi, Alessandro Rambaldi, Tobias Gedde-Dahl, Eleni Tholouli, Nicolaus Kröger, Jean-Henri Bourhis, Peter A. Von Dem Borne, Etienne Daguindau, Édouard Forcade, Arnon Nagler, Jordi Esteve, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2023-185434

Published: 2023

Journal Articles

Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Peter A. Von Dem Borne, Berit M. Kemps-Mols, Liesbeth C. de Wreede, Adriaan A. van Beek, Tjeerd J.F. Snijders, Danielle van Lammeren, Janneke Tijmensen, Aniko Sijs-Szabo, Theo L. Nering Bögel, Mirjam A. Oudshoorn, Constantijn J.M. Halkes, Peter van Balen, Erik W.A.F. Marijt, Jennifer M.L. Tjon, Joost S.P. Vermaat, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 4735–4736.

https://doi.org/10.1182/blood-2022-157012

Published: 2022

Journal Articles

Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia

Peter A. Von Dem Borne, Tjeerd J.F. Snijders, Danielle van Lammeren, Janneke Tijmensen, Erwin V. Planken, Henriette Levenga, Yascha van den Berg, Erik WAF Marijt, Peter van Balen, Jennifer M. Tjon, Joost S.P. Vermaat, Theo L. Nering Bögel, Mirjam A. Oudshoorn, Constantijn J.M. Halkes, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 7742–7743.

https://doi.org/10.1182/blood-2022-157894

Published: 2022

Journal Articles

Excessive Early Death after Intensive Chemotherapy for Acute Myeloid Leukemia Occurs in Patients over 65 Years with High Co-Morbidity, and in Patients over 50 Years with High Co-Morbidity When Postponed Early Death Is Included

J Claire Sinigaglia, Liesbeth C de Wreede, PhD, Hendrik Veelken, MD PhD, Peter A. Von Dem Borne, MD PhD

Blood (2017) 130 (Supplement 1): 1316.

https://doi.org/10.1182/blood.V130.Suppl_1.1316.1316

Published: 2017

Journal Articles

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

Raphael Carapito, Nicolas Jung, Marius Kwemou, Meiggie Untrau, Sandra Michel, Angélique Pichot, Gaëlle Giacometti, Cécile Macquin, Wassila Ilias, Aurore Morlon, Irina Kotova, Petya Apostolova, Annette Schmitt-Graeff, Anne Cesbron, Katia Gagne, Machteld Oudshoorn, Bronno van der Holt, Myriam Labalette, Eric Spierings, Christophe Picard, Pascale Loiseau, Ryad Tamouza, Antoine Toubert, Anne Parissiadis, Valérie Dubois, Xavier Lafarge, Myriam Maumy-Bertrand, Frédéric Bertrand, Luca Vago, Fabio Ciceri, Catherine Paillard, Sergi Querol, Jorge Sierra, Katharina Fleischhauer, Arnon Nagler, Myriam Labopin, Hidetoshi Inoko, Peter A. von dem Borne, Jürgen Kuball, Masao Ota, Yoshihiko Katsuyama, Mauricette Michallet, Bruno Lioure, Régis Peffault de Latour, Didier Blaise, Jan J. Cornelissen, Ibrahim Yakoub-Agha, Frans Claas, Philippe Moreau, Noël Milpied, Dominique Charron, Mohamad Mohty, Robert Zeiser, Gérard Socié, Seiamak Bahram

Blood (2016) 128 (15): 1979–1986.

https://doi.org/10.1182/blood-2016-05-719070

Published: 2016

Includes: Supplemental data

Journal Articles

The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Giorgia Battipaglia, Myriam Labopin, MD, Anna Candoni, MD, Renato Fanin, Jean El Cheikh, Didier Blaise, Mauricette Michallet, MD PhD, Annalisa Ruggeri, MD PhD, Natalie Contentin, Josep Ribera, MD PhD, Michael Stadler, MD, Jorge Sierra, MD PhD, Peter A. Von Dem Borne, Adrian Bloor, FRCPath, Gerard Socie, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3110.

https://doi.org/10.1182/blood.V126.23.3110.3110

Published: 2015

Journal Articles

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

Peter A. Von Dem Borne, MD, PhD, Constantijn J.M. Halkes, MD, PhD, Erik W.A. Marijt, MD, PhD, Sabina Kersting, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, J.Hendrik Veelken, MD, PhD

Blood (2012) 120 (21): 3085.

https://doi.org/10.1182/blood.V120.21.3085.3085

Published: 2012

Journal Articles

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD, Judith Olde Wolbers, Esther M van Egmond, Peter A. Von Dem Borne, MD, PhD, Erik W.A.F. Marijt, MD, PhD, J.H.Frederik Falkenburg, MD, PhD

Blood (2010) 116 (21): 2330.

https://doi.org/10.1182/blood.V116.21.2330.2330

Published: 2010

Journal Articles

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Tom Lodewyck, MD, Machteld Oudshoorn, PhD, Bronno van der Holt, PhD, Eefke Petersen, MD, PhD, Eric Spierings, PhD, Peter A. Von Dem Borne, MD, PhD, Anton Schattenberg, MD, PhD, Wil Allebes, PhD, Ellen Meijer, MD, PhD, Marlies Groenendijk-Sijnke, Lucia Duinhouwer, Roelof Willemze, MD, PhD, Leo F. Verdonck, MD, PhD, Bob Lowenberg, MD, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 1196.

https://doi.org/10.1182/blood.V114.22.1196.1196

Published: 2009

Journal Articles

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD PhD, Roelof Willemze, MD PhD, J.H. Frederik Falkenburg, MD PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 2454.

https://doi.org/10.1182/blood.V114.22.2454.2454

Published: 2009

Journal Articles

Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.

Grzegorz Wladyslaw Basak, Anja van Biezen, Ronald Brand, Christoph Schmid, Cesare Guglielmi, Anton Schattenberg, Richard Szydlo, Peter A. Von Dem Borne, Leo Verdonck, Donald W. Bunjes, Wieslaw Wiktor-Jedrzejczak, Eduardo Olavarria, Theo de Witte

Blood (2009) 114 (22): 3309.

https://doi.org/10.1182/blood.V114.22.3309.3309

Published: 2009

Journal Articles

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD, PhD, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 3552.

https://doi.org/10.1182/blood.V114.22.3552.3552

Published: 2009

Journal Articles

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Gerard M.J. Bos, MD, PhD, Sandra Croockewit, MD, PhD, Jan J. Cornelissen, MD, PhD, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, MD, PhD, Michel Delforge, MD, PhD, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, MD, PhD, Edo Vellenga, MD, PhD, Asiong Jie, Henriette Berenschot, MD, PhD, Marinus Marwijk-kooy, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2008) 112 (11): 157.

https://doi.org/10.1182/blood.V112.11.157.157

Published: 2008

Journal Articles

The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation.

Peter A. Von Dem Borne, C.W.J. Ingrid Starrenburg, M. Floor Beaumont, Stijn J.M. Halkes, Erik W.A. Marijt, J.H. Frederik Falkenburg, Roelof Willemze

Blood (2008) 112 (11): 2218.

https://doi.org/10.1182/blood.V112.11.2218.2218

Published: 2008

Journal Articles

SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

Pleun Hombrink, MSc, Sine R Hadrup, PhD, Arne Bakker, PhD, J.H. Frederik Falkenburg, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Ton N Schumacher, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2008) 112 (11): 814.

https://doi.org/10.1182/blood.V112.11.814.814

Published: 2008

NARROW

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Mismatched Unrelated Donor Transplantation with Ptcy-Based Gvhd Prophylaxis Is Associated with Better Survival Than Double Unit Umbilical Cord Blood Transplantation in Patients with AML in First CR: A Study from the ALWP of the EBMT

Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Randomized Trial of Prophylactic Donor Lymphocyte Infusion with Positively Selected CD4+ T Cells after HLA-Identical Allogeneic Stem Cell Transplantation

Should the European Leukemia Net 2022 Adverse Risk Classification of NPM1 mutated Acute Myeloid Leukemia be Revisited? Among Adverse Risk Cytogenetics, Solely Complex Karyotype Is Associated with Worse Post-Transplant Survival: A Study from the EBMT Acute Leukemia Working Party

Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia

Excessive Early Death after Intensive Chemotherapy for Acute Myeloid Leukemia Occurs in Patients over 65 Years with High Co-Morbidity, and in Patients over 50 Years with High Co-Morbidity When Postponed Early Death Is Included

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

The Risk of Sinusoidal Obstruction Syndrome (SOS) in Allogeneic Hematopoietic Stem Cell Transplantation after Prior Gemtuzumab Ozogamicin Treatment: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation.

SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only